)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Chugai Pharmaceutical Co (4519) investor relations material
Chugai Pharmaceutical Co Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary24 Jul, 2025
Executive summary
Revenue and profit increased year-over-year, driven by strong domestic and overseas sales, especially Actemra and HEMLIBRA, and new product launches.
Strategic R&D reprioritization led to discontinuation of five early-stage projects, reallocating resources to higher-priority candidates.
Major investment of ¥80 billion approved for a new R&D facility (UKX) at the Ukima site to support increased project volume and complex drug development.
Key R&D milestones achieved, including successful P3 trial of orforglipron and PoC confirmation in NXT007.
Special 100th Anniversary dividends declared, with total forecasted annual dividend per share at ¥250.00.
Financial highlights
Revenue for Jan–Jun 2025: ¥578.5B (+4.6% YoY); operating profit: ¥273.3B (+5.8% YoY); net income: ¥194.4B (+4.3% YoY).
Domestic sales: ¥223.3B (+2.8% YoY); overseas sales: ¥288.1B (+7.3% YoY), led by Actemra exports.
Cost to sales ratio increased to 34.3% due to product mix changes.
SG&A expenses decreased YoY due to operational efficiency, despite inflation and personnel cost increases.
Earnings per share (basic): ¥118.13 (vs. ¥113.20 YoY).
Outlook and guidance
Full-year revenue and profit are expected to meet or exceed initial forecasts, with HEMLIBRA and Actemra projected to surpass targets.
Annual dividend per share forecast: ¥250.00, including ¥150.00 special dividend for the 100th Anniversary.
No changes to previously announced full-year forecasts.
FX impact, especially yen depreciation, provided a significant positive effect on revenue.
Delayed revenue recognition for HEMLIBRA in Q2 will be booked in Q3, supporting a positive outlook.
How will UKX building foster innovation?
Explain the impact of generic drugs.
What is driving Actemra export growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Chugai Pharmaceutical Co earnings date
Q3 202524 Oct, 2025
Next Chugai Pharmaceutical Co earnings date
Q3 202524 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Chugai Pharmaceutical Co., Ltd., operating under the umbrella of F. Hoffmann-La Roche Ltd, is a notable player in the pharmaceutical industry, mainly in Japan. Chugai is dedicated to the research, development, commercialization, and manufacture of biopharmaceuticals and therapeutic antibodies. The company's product range focuses on several therapeutic areas such as cancer, bone and joint diseases, renal diseases, and immune disorders, among others. It also plays a significant role in the global healthcare market through its international operations in North America, Europe, and other regions in Asia. Chugai Pharmaceutical is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage